LYEL
Lyell Immunopharma, Inc.$10.94-0.10 (-0.91%)Prev Close$11.04·MCap$279.3M·P/E—·Vol41.9K·Yield—
▲
Buys (12M)
2
$25.00M
▼
Sells (12M)
28
$608.2K
◆
Net Activity
Net Buyer
$24.39M
●
Active Insiders
9
last 12 mo
Over the past 12 months, insider activity at Lyell Immunopharma, Inc. (LYEL) has been dominated by buying, with 2 insider purchases totaling $25.00M and 28 insider sales totaling $608.2K. The most recent insider transaction was by Aguirre Jarrad Mattieu (officer: Chief Medical Officer), who sold $3.6K worth of shares on Oct 13, 2026. Lyell Immunopharma, Inc. operates in the Healthcare sector, within the Biotechnology industry, with a market cap of $279.3M.
LYEL Insider Trading Activity
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Oct 13, 2026 | Aguirre Jarrad Mattieu | officer: Chief Medical Officer | Sell | 422 | $8.63 | $3.6K | 19,857 |
| Sep 10, 2026 | Shook David | officer: Chief Medical Officer | Sell | 500 | $12.70 | $6.3K | 20,423 |
| Aug 25, 2026 | Seely Lynn | director, officer: President and CEO | Sell | 9,589 | $15.54 | $149.0K | 63,899 |
| Aug 25, 2026 | Hill Stephen J. | officer: Chief Operating Officer | Sell | 989 | $15.54 | $15.4K | 16,816 |
| Aug 25, 2026 | Lee Gary K. | officer: Chief Scientific Officer | Sell | 1,457 | $15.54 | $22.6K | 16,220 |
| Aug 11, 2026 | Seely Lynn | director, officer: President and CEO | Sell | 390 | $14.34 | $5.6K | 73,488 |
| Aug 11, 2026 | Bulis Veronica Sanchez | officer: VP, Corporate Controller | Sell | 621 | $14.34 | $8.9K | 14,799 |
| Aug 11, 2026 | Hill Stephen J. | officer: Chief Operating Officer | Sell | 89 | $14.34 | $1.3K | 17,805 |
| Aug 11, 2026 | Lee Gary K. | officer: Chief Scientific Officer | Sell | 131 | $14.34 | $1.9K | 17,677 |
| Jul 20, 2026 | Innovative Cellular Therapeutics Holdings Ltd | 10 percent owner | Sell | 10 | $13.70 | $137.00 | 2,857,480 |
| Jul 17, 2026 | Innovative Cellular Therapeutics Holdings Ltd | 10 percent owner | Sell | 10 | $13.73 | $137.30 | 2,857,490 |
| Jun 15, 2026 | Seely Lynn | director, officer: President and CEO | Sell | 388 | $18.91 | $7.3K | 73,878 |
| Jun 15, 2026 | Hill Stephen J. | officer: Chief Operating Officer | Sell | 89 | $18.92 | $1.7K | 17,894 |
| Jun 15, 2026 | Lee Gary K. | officer: Chief Scientific Officer | Sell | 130 | $18.92 | $2.5K | 17,808 |
| Jun 15, 2026 | Bulis Veronica Sanchez | officer: VP, Corporate Controller | Sell | 217 | $18.91 | $4.1K | 15,420 |
| Jun 11, 2026 | Shook David | officer: Chief Medical Officer | Sell | 1,977 | $12.64 | $25.0K | 20,923 |
| Mar 9, 2026 | ARCH Venture Fund XIII, L.P. | 10 percent owner | Buy | 488,090 | $25.61 | $12.50M2.1% OS | 1,426,528+52% |
| Mar 9, 2026 | ARCH Venture Partners IX, LLC | 10 percent owner | Buy | 488,090 | $25.61 | $12.50M2.1% OS | 1,426,528+52% |
| Feb 11, 2026 | Hill Stephen J. | Chief Operating Officer | Sell | 1,236 | $23.39 | $28.9K | 0 |
| Feb 11, 2026 | Lee Gary K. | Chief Scientific Officer | Sell | 1,671 | $23.39 | $39.1K | 0 |
| Feb 11, 2026 | Seely Lynn | President and CEO | Sell | 7,455 | $23.39 | $174.4K | 0 |
| Feb 10, 2026 | Bulis Veronica Sanchez | VP, Corporate Controller | Sell | 254 | $23.12 | $5.9K | 0 |
| Feb 9, 2026 | Hill Stephen J. | Chief Operating Officer | Sell | 109 | $23.12 | $2.5K | 0 |
| Feb 9, 2026 | Lee Gary K. | Chief Scientific Officer | Sell | 147 | $23.12 | $3.4K | 0 |
| Feb 9, 2026 | Seely Lynn | President and CEO | Sell | 438 | $23.12 | $10.1K | 0 |
| Dec 24, 2025 | Bulis Veronica Sanchez | VP, Corporate Controller | Sell | 2,072 | $35.80 | $74.2K | 0 |
| Nov 10, 2025 | Bulis Veronica Sanchez | VP, Corporate Controller | Sell | 239 | $16.10 | $3.8K | 0 |
| Nov 10, 2025 | Hill Stephen J. | Chief Operating Officer | Sell | 95 | $16.12 | $1.5K | 0 |
| Nov 10, 2025 | Lee Gary K. | Chief Scientific Officer | Sell | 138 | $16.16 | $2.2K | 0 |
| Nov 10, 2025 | Seely Lynn | President and CEO | Sell | 412 | $16.11 | $6.6K | 0 |
| Aug 20, 2025 | Hill Stephen J. | Chief Operating Officer | Sell | 1,004 | $10.54 | $10.6K | 0 |
| Aug 20, 2025 | Newton Charles W. | Chief Financial Officer | Sell | 1,453 | $10.54 | $15.3K | 0 |
| Aug 20, 2025 | Seely Lynn | President and CEO | Sell | 7,257 | $10.54 | $76.5K | 0 |
| Aug 11, 2025 | Hill Stephen J. | Chief Operating Officer | Sell | 185 | $10.43 | $1.9K | 0 |
| Aug 11, 2025 | Lee Gary K. | Chief Scientific Officer | Sell | 267 | $10.43 | $2.8K | 0 |
| Aug 11, 2025 | Seely Lynn | President and CEO | Sell | 797 | $10.43 | $8.3K | 0 |
| Mar 31, 2025 | BRAWLEY OTIS W | Director | Buy | 35,640 | $0.56 | $20.0K | 0 |
| Mar 21, 2025 | Ramachandra Sumant | Director | Buy | 200,000 | $0.58 | $115.2K0.9% OS | 0 |
| Mar 17, 2025 | Newton Charles W. | Chief Financial Officer | Buy | 200,000 | $0.56 | $111.6K0.9% OS | 0 |
| Mar 14, 2025 | Klausner Richard | Director | Buy | 158,000 | $0.60 | $94.9K0.7% OS | 0 |
| Mar 14, 2025 | Seely Lynn | President and CEO | Buy | 175,000 | $0.61 | $106.2K0.8% OS | 0 |
| Aug 17, 2023 | Klausner Richard | Director | Sell | 58,020 | $2.28 | $132.3K | 930,880 |
| Sep 27, 2022 | Klausner Richard | Director | Sell | 11,100 | $6.40 | $71.0K | 988,900 |
| Jun 23, 2021 | FRIEDMAN CATHY | Director | Buy | 17,648 | $17.00 | $300.0K | 17,648 |
LYEL Insider Buying Activity
The following table shows recent insider purchases of Lyell Immunopharma, Inc. (LYEL) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Mar 9, 2026 | ARCH Venture Fund XIII, L.P. | 10 percent owner | Buy | 488,090 | $25.61 | $12.50M2.1% OS | 1,426,528+52% |
| Mar 9, 2026 | ARCH Venture Partners IX, LLC | 10 percent owner | Buy | 488,090 | $25.61 | $12.50M2.1% OS | 1,426,528+52% |
| Mar 31, 2025 | BRAWLEY OTIS W | Director | Buy | 35,640 | $0.56 | $20.0K | 0 |
| Mar 21, 2025 | Ramachandra Sumant | Director | Buy | 200,000 | $0.58 | $115.2K0.9% OS | 0 |
| Mar 17, 2025 | Newton Charles W. | Chief Financial Officer | Buy | 200,000 | $0.56 | $111.6K0.9% OS | 0 |
| Mar 14, 2025 | Klausner Richard | Director | Buy | 158,000 | $0.60 | $94.9K0.7% OS | 0 |
| Mar 14, 2025 | Seely Lynn | President and CEO | Buy | 175,000 | $0.61 | $106.2K0.8% OS | 0 |
| Jun 23, 2021 | FRIEDMAN CATHY | Director | Buy | 17,648 | $17.00 | $300.0K | 17,648 |
LYEL Insider Selling Activity
The following table shows recent insider sales of Lyell Immunopharma, Inc. (LYEL) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Oct 13, 2026 | Aguirre Jarrad Mattieu | officer: Chief Medical Officer | Sell | 422 | $8.63 | $3.6K | 19,857 |
| Sep 10, 2026 | Shook David | officer: Chief Medical Officer | Sell | 500 | $12.70 | $6.3K | 20,423 |
| Aug 25, 2026 | Seely Lynn | director, officer: President and CEO | Sell | 9,589 | $15.54 | $149.0K | 63,899 |
| Aug 25, 2026 | Hill Stephen J. | officer: Chief Operating Officer | Sell | 989 | $15.54 | $15.4K | 16,816 |
| Aug 25, 2026 | Lee Gary K. | officer: Chief Scientific Officer | Sell | 1,457 | $15.54 | $22.6K | 16,220 |
| Aug 11, 2026 | Seely Lynn | director, officer: President and CEO | Sell | 390 | $14.34 | $5.6K | 73,488 |
| Aug 11, 2026 | Bulis Veronica Sanchez | officer: VP, Corporate Controller | Sell | 621 | $14.34 | $8.9K | 14,799 |
| Aug 11, 2026 | Hill Stephen J. | officer: Chief Operating Officer | Sell | 89 | $14.34 | $1.3K | 17,805 |
| Aug 11, 2026 | Lee Gary K. | officer: Chief Scientific Officer | Sell | 131 | $14.34 | $1.9K | 17,677 |
| Jul 20, 2026 | Innovative Cellular Therapeutics Holdings Ltd | 10 percent owner | Sell | 10 | $13.70 | $137.00 | 2,857,480 |
| Jul 17, 2026 | Innovative Cellular Therapeutics Holdings Ltd | 10 percent owner | Sell | 10 | $13.73 | $137.30 | 2,857,490 |
| Jun 15, 2026 | Seely Lynn | director, officer: President and CEO | Sell | 388 | $18.91 | $7.3K | 73,878 |
| Jun 15, 2026 | Hill Stephen J. | officer: Chief Operating Officer | Sell | 89 | $18.92 | $1.7K | 17,894 |
| Jun 15, 2026 | Lee Gary K. | officer: Chief Scientific Officer | Sell | 130 | $18.92 | $2.5K | 17,808 |
| Jun 15, 2026 | Bulis Veronica Sanchez | officer: VP, Corporate Controller | Sell | 217 | $18.91 | $4.1K | 15,420 |
| Jun 11, 2026 | Shook David | officer: Chief Medical Officer | Sell | 1,977 | $12.64 | $25.0K | 20,923 |
| Feb 11, 2026 | Hill Stephen J. | Chief Operating Officer | Sell | 1,236 | $23.39 | $28.9K | 0 |
| Feb 11, 2026 | Lee Gary K. | Chief Scientific Officer | Sell | 1,671 | $23.39 | $39.1K | 0 |
| Feb 11, 2026 | Seely Lynn | President and CEO | Sell | 7,455 | $23.39 | $174.4K | 0 |
| Feb 10, 2026 | Bulis Veronica Sanchez | VP, Corporate Controller | Sell | 254 | $23.12 | $5.9K | 0 |
| Feb 9, 2026 | Hill Stephen J. | Chief Operating Officer | Sell | 109 | $23.12 | $2.5K | 0 |
| Feb 9, 2026 | Lee Gary K. | Chief Scientific Officer | Sell | 147 | $23.12 | $3.4K | 0 |
| Feb 9, 2026 | Seely Lynn | President and CEO | Sell | 438 | $23.12 | $10.1K | 0 |
| Dec 24, 2025 | Bulis Veronica Sanchez | VP, Corporate Controller | Sell | 2,072 | $35.80 | $74.2K | 0 |
| Nov 10, 2025 | Bulis Veronica Sanchez | VP, Corporate Controller | Sell | 239 | $16.10 | $3.8K | 0 |
| Nov 10, 2025 | Hill Stephen J. | Chief Operating Officer | Sell | 95 | $16.12 | $1.5K | 0 |
| Nov 10, 2025 | Lee Gary K. | Chief Scientific Officer | Sell | 138 | $16.16 | $2.2K | 0 |
| Nov 10, 2025 | Seely Lynn | President and CEO | Sell | 412 | $16.11 | $6.6K | 0 |
| Aug 20, 2025 | Hill Stephen J. | Chief Operating Officer | Sell | 1,004 | $10.54 | $10.6K | 0 |
| Aug 20, 2025 | Newton Charles W. | Chief Financial Officer | Sell | 1,453 | $10.54 | $15.3K | 0 |
| Aug 20, 2025 | Seely Lynn | President and CEO | Sell | 7,257 | $10.54 | $76.5K | 0 |
| Aug 11, 2025 | Hill Stephen J. | Chief Operating Officer | Sell | 185 | $10.43 | $1.9K | 0 |
| Aug 11, 2025 | Lee Gary K. | Chief Scientific Officer | Sell | 267 | $10.43 | $2.8K | 0 |
| Aug 11, 2025 | Seely Lynn | President and CEO | Sell | 797 | $10.43 | $8.3K | 0 |
| Aug 17, 2023 | Klausner Richard | Director | Sell | 58,020 | $2.28 | $132.3K | 930,880 |
| Sep 27, 2022 | Klausner Richard | Director | Sell | 11,100 | $6.40 | $71.0K | 988,900 |
LYEL Insiders
Similar Stocks to LYEL
MRNA
Moderna, Inc.
$226.63+2.24%
$85.50B
REGN
Regeneron Pharmaceuticals, Inc.
$967.25+4.30%
$83.15B
RVMD
Revolution Medicines, Inc.
$189.50-0.95%
$39.42B
ALNY
Alnylam Pharmaceuticals, Inc.
$161.40-2.21%
$30.46B
UTHR
United Therapeutics Corporation
$596.00-0.45%
$25.15B
INCY
Incyte Corporation
$119.18-0.92%
$23.69B
INSM
Insmed Incorporated
$110.41-1.93%
$21.18B
EXEL
Exelixis, Inc.
$71.86+3.59%
$16.64B